NCT07103382Recruiting
Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
Source: ClinicalTrials.gov · Last updated 5 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 10 Jul 2025
- Start date
- 26 Jun 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Diseases
- Obesity
- NCT number
- NCT07103382
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 26 Jun 2025 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections
- History of gastrointestinal surgery (such as cholecystectomy) within the past year or non-gastrointestinal surgery within six months, or prior bariatric surgery
- Use of probiotics, prebiotics, or antibiotics within three months prior to enrollment, or alcohol abuse; Consumption of yogurt within two weeks before the study or during the trial period; History of psychiatric or infectious diseases
Other illness
- Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes
- Obesity or overweight due to endocrine disorders (such as thyroid dysfunction or Cushing's syndrome)
- Uncontrolled hypertension, severe cardiac/hepatic/renal dysfunction
- Chronic gastrointestinal disorders (such as recurrent constipation, celiac disease, or food intolerances) or any condition impairing digestion/absorption function
- History of malignant tumors within five years, regardless of whether there is recurrence or metastasis and severe immune dysfunction (such as malignant tumors, HIV/AIDS, immunodeficiency diseases)
- Any condition that in the judgement of the investigator precludes participation
Other
- Use of weight-affecting products within the past three months or planned use during the study
- Weight fluctuation \>5 kg or \>10% within the past three months
- Pregnancy, lactation, or plans for pregnancy during the study
- Participation in other clinical trials within the past three months
Who the study is looking for
- Obese individuals:
- Aged 18-60 years, regardless of sex/gender
- BMI≥28.0kg/m2
- Overweight or obese individuals with type 2 diabetes:
- Aged 18-60 years, regardless of sex/gender
- BMI≥24.0kg/m2
- HbA1c ≥7.0% and ≤10.0% or the fasting blood glucose ≥7.0 mmol/l and ≤ 13.3 mmol/l at screening
- Stable diabetes treatment for at least 6 months or more
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.